Revenue segments as reported by the company.

Cannabis revenue

Distribution revenue

Beverage alcohol revenue

Wellness revenue

Adult-use

Canada - Medical

International - Medical

Bulk

Hemp

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Impairment of Assets

Litigation settlement

Transaction costs

Change in fair value of contingent consideration

Restructuring costs

Other than temporary change in fair value of convertible notes receivable

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Tilray Brands

Tilray Brands, Inc. is a global cannabis-lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America. The firm is focused on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. Its products include dried cannabis and cannabis extracts. It operates through the following segments: Cannabis and Hemp. The Cannabis segment consists of adult-use, medical and bulk sales of cannabis under regulated licenses and sold to retail, wholesale, pharmacy, government, and direct to patient. The Hemp segment consists of hemp seed, hemp foods, and broad spectrum hemp extract containing CBD, which are sold in an unlicensed operation and sold to retail, wholesale and direct to consumers. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Earnings data Q1 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Tilray Brands reports record revenue and optimistic outlook for 2025

Tilray Brands achieved remarkable financial performance in Q4 2024, driven by strategic acquisitions and a focus on innovation. Despite challenges like price compression, the company remains optimistic about future growth opportunities. Tilray's commitment to quality products and innovation positions it well for continued success in the market.

Tilray Brands reports record Q1 revenue growth and global expansion

Tilray Brands delivered a robust performance in Q1 2025, showcasing strong revenue growth, margin improvement, and strategic expansion across its diversified product portfolio.
While facing challenges in a competitive landscape and evolving regulatory environment, Tilray's financial strength, international growth initiatives, and focus on innovation position it well for future success.
By capitalizing on opportunities in wellness products, expanding into new beverage categories, and leveraging strategic partnerships, Tilray is poised for continued growth and market leadership.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Tilray Brands, Inc. is a global cannabis-lifestyle and consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, and Wellness Business. The Cannabis Business segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution Business segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage Alcohol Business segment refers to the production, marketing, and sale of beverages. The Wellness Business segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Canopy Growth

Cronos Group

Canopy Growth (CGC), Tilray (TLRY) and Cronos (CRON) shoot up on news that the DEA is considering recommendations for low-risk reclassification of marijuana.

3 Cannabis Stocks Soaring on HHS' Recommendation to DEA

Brinker International

Groupon

Recently released macro economic data is indicating that the United States economy is heading for a “soft landing.” Specifically, according to the Department of Labor's  Job Openings and Labor Turnover Survey (JOLTS) for July, “2.3%  of nonfarm payroll workers quit their jobs” last month, versus the high of 35 during the “Great Resignation.

3 Beaten-Down Stocks Due for a Massive Short Squeeze

Curaleaf Holdings, Inc.

Green Thumb Industries Inc.

The recommendation is part of a larger marijuana reform plan announced by the Biden Administration last year.

Cannabis Stocks Surge After HHS Recommends Classifying Marijuana As Lower-Risk Drug

Aurora Cannabis

If marijuana is downgraded to a Schedule III drug, it could be a huge boost to a struggling industry.

U.S. health officials want to loosen marijuana restrictions. Here's what it means

Cannabis stocks are celebrating this morning after the U.S. Department of Health and Human Services recommended in a letter to the Drug Enforcement Administration that Marijuana be reclassified as a Schedule III drug.

Why are cannabis stocks trading significantly up on Thursday?

Amplify Alternative Harvest ETF

AdvisorShares Pure US Cannabis ETF

Global X Cannabis ETF

Trulieve Cannabis Corp.

The move by the Drug Enforcement Administration to review the Schedule I classification for cannabis sparked a wave of speculation and mostly positive comments from Wall Street on Thursday, but many questions remain.

HHS recommendation to reschedule cannabis keeps pot stocks hot, but questions remain

Bright Green Corp

SNDL Inc.

The cannabis sector is one of the most challenging sectors in the market, leading to speculative cannabis stocks. If you've been following it for the last few years, you know the roller coaster ride investors have ridden.

High Risk, High Reward: 3 Cannabis Stocks for the Bold Trader

Tilray (NASDAQ: TLRY ), a Canada-based cannabis company, is trending, and TLRY stock is up about 5% in early trading after jumping nearly 11% yesterday. The rally was sparked by a report that the U.S. Department of Health and Human Services (HHS) has recommended that the federal government fundamentally change its official view of cannabis.

TLRY Stock Alert: Watch This Upside Catalyst for Tilray Closely

Cannabis stocks are up on Thursday as investors in the market react to news marijuana may be downgraded from a Schedule I drug. According to insiders, a member of the Department of Health and Human Services is seeking a drop in the drug from Schedule I to Schedule III.

Why Are Cannabis Stocks TLRY, ACB, CGC, CURLF Up Today?

Innovative Industrial Properties

The U.S. government appears finally to be ready to review its categorization of marijuana as a dangerous drug, reviving hope among investors and marijuana producers for an industry that took off like a rocket five years ago before sinking like a rock less than two years later.

Will a Change to US Marijuana Policy Save Any of the Weed Companies?

Assistant Secretary for Health Rachel Levine reportedly requested in a letter to DEA Administrator Anne Milgram that marijuana be downgraded to a schedule III substance.

Pot stocks rally after health officials ask DEA to reclassify marijuana as lower-risk drug

Roundhill Cannabis ETF

The Drug Enforcement Agency received an official recommendation to downgrade marijuana.  Currently, pot is classified as a Schedule I drug, on par with heroin.

Pot stocks jump as federal agency reportedly seeks to downgrade cannabis from the hard-drug category

President Joe Biden is asking the DEA to reclassify marijuana as a Schedule III drug. The DEA has the authority to reschedule a drug under the Controlled Substances Act.

Why Tilray Stock Surged Today

That move could potentially expand the market for cannabis, sending shares of Canopy Growth, Tilray Brands and Cronos Group higher.

HHS calls for easing restrictions on marijuana, sending cannabis stocks higher

Ardelyx

EVgo

There's a certain allure in the world of penny stocks. For savvy investors, the promise of top penny stock picks is too enticing to resist, especially when you can scoop up several shares with a $100 bill.

The 3 Most Promising Penny Stocks to Own Now

The U.S. Department of Health and Human Services is recommending to the U.S. Drug Enforcement Administration that cannabis should be reclassified as a Schedule III controlled substance under U.S. law from Schedule I now, according to a report by Bloomberg. Cannabis stocks are rallying, with the AdviserShares Pure US Cannabis ETF MSOS, +18.76% up by nearly 33%, and the ETFMG Alternative Harvest ETF MJ, +10.27% up by 19.5%.

U.S. Dept. of Health and Human Services recommends re-scheduling cannabis, as stocks in the sector rally

Tilray has a trio of hurdles to clear if it wants to delight investors. Its alcohol segment's profitability and its cannabis sales will be key to watch.

3 Key Tests for Tilray Stock in Fall 2023

The New Hand-Crafted RIFF Diamond Infused Pre-rolls and Blunts Are Now Available in Ontario PURE ‘DIAMONDS COLLECTION' IS ‘A CUT ABOVE'    TORONTO, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis and consumer packaged goods company, today debuts its new ‘Diamonds Collection' by its Premium cannabis lifestyle brand RIFF . Introducing its new Diamond Infused Pre-rolls, including Melonaide and Purple Punch OG strains, and '26 Delta Diamond Infused Blunts featuring Blue CKS featuring Girl Scout Cookies (GSC) lineage and Blueberry Kush, both produced with small-batch, hand-crafted whole flower boosted by THCA diamonds and premium full spectrum resin.

RIFF Cannabis Launches New Diamond Infused Pre-Rolls and Blunts

AdvisorShares, the company managing the world's largest hemp exchange-traded fund Poseidon Dynamic Cannabis ETF (NYSEARCA:PSDN), has reported a waning interest in cannabis stocks. The cannabis industry in the U.S. faces harsh realities of supply surplus, declining wholesale prices, stricter regulations, and distribution challenges.

3 Undervalued Cannabis Stocks With Sky-High Return Potential

With the chances of marijuana companies accessing the U.S. financial system higher than ever and cannabis stocks trading at lower valuations than ever before, now looks like an excellent time to seek out top-notch cannabis stocks to buy. Regarding access to the American financial system, Senate Majority Leader Chuck Schumer, a Democrat, appears to be working hard to enable the cannabis sector to obtain this much-needed change.

These Are the ONLY 3 Cannabis Stocks to Consider in August 2023

Founded as a pure-play marijuana business, the company has lately been pivoting. Tilray is attempting to become a major purveyer in the U.S. craft beer business.

Could Tilray Stock Help You Become a Millionaire?

Village Farms International

Marijuana stock investors are looking to see better trading this week. Over the last few months, there has been an ongoing decline for most of the sector. Now over the last 4 to 6 weeks, there has been some volatile pops for cannabis stocks. Back at the start of August news on a new federal reform bill led to seeing a slight recovery. Also, this month cannabis companies released their Q2 2023 financial results.

3 Canadian Marijuana Stocks To Buy This Week 2023

Bitfarms Ltd

Kinross Gold

Polestar Automotive Holding UK PLC

Solid Power

Standard Lithium Ltd

With markets showing signs of strength again, I wanted to take a look at a few oversold opportunities on the market, namely oversold penny stocks. While I believe each could return multi-bagger returns, let's be clear about a few things.

7 Very Oversold Penny Stocks to Buy Right Now

Constellation Brands

Molson Coors Brewing

The number of adults age 34 and younger who say they drink alcoholic beverages has dropped during a period of rising cannabis use, according to new survey from Gallup.

Alcohol use drops among young adults, while cannabis consumption grows: Gallup poll

Axsome Therapeutics

Hormel Foods

Axsome's two new products have the potential to generate exceptional growth. Hormel Foods' resilience is impressive, even in an inflationary market.

These 3 Stocks Have Underperformed the Market This Year. Is Now the Time to Buy?

News for Tilray Brands Stock (TLRY)